India's First Alzheimer's Drug Approved Amid Rising Dementia Cases
With 8.8 million Indians over 60 affected by dementia, experts stress the need for early diagnosis alongside new treatments.
8.8 million Indians aged 60 and above are living with dementia, primarily Alzheimer's.
Lecanemab, India's first disease-modifying Alzheimer's drug, is approved for early-stage patients.
Access to diagnostic infrastructure remains a significant barrier, especially in rural areas.
India is witnessing a significant rise in dementia cases, with approximately 8.8 million individuals aged over 60 currently affected. Alzheimer's disease constitutes nearly two-thirds of these cases, highlighting a growing public health concern. Despite the recent approval of lecanemab, marketed as LEQEMBI, as the first disease-modifying therapy for Alzheimer's in India, healthcare professionals emphasize that effective diagnosis and treatment are crucial for patient benefit.
For nearly 30 years, treatment options for Alzheimer's were limited to symptomatic relief, failing to address the underlying disease. The introduction of lecanemab marks a pivotal moment, as it targets the biological processes of Alzheimer's rather than merely alleviating symptoms. Dr. Madhukar Bharadwaj, Director of Neurology at Aakash Healthcare, notes that this approval has transformed discussions with families, who have long sought ways to slow the disease's progression.
However, the approval comes with specific conditions. Lecanemab is intended for patients in the early stages of Alzheimer's, specifically those with mild cognitive impairment or mild dementia. Prior to treatment, doctors must confirm the presence of amyloid pathology through cerebrospinal fluid analysis or blood tests. This requirement underscores the need for timely diagnosis, as patients with mild forgetfulness can no longer afford to wait for intervention, which is critical for treatment efficacy.
The challenges extend beyond medical criteria, as there is a pressing need for improved primary care referral systems and cognitive screening at initial points of contact. Dr. Neha Kapoor from Asian Hospital highlights that many individuals mistakenly attribute memory decline to aging, delaying their hospital visits until the disease has progressed significantly. This gap in access is particularly pronounced in rural and semi-urban areas, where medical resources for early detection are scarce.
Dr. Rajas Deshpande from Jupiter Hospital points out that the necessary infrastructure for administering lecanemab, including advanced diagnostic testing, is predominantly available in major metropolitan areas. Consequently, patients in smaller towns often face logistical hurdles in accessing timely care. Addressing these barriers requires a concerted effort to enhance community-level cognitive screening, training for primary care providers, and public awareness initiatives in local languages to ensure that early-stage Alzheimer's and related health issues are recognized and treated effectively.
